CN101287714B - 前列腺素d2受体拮抗剂的磷酸二氢盐 - Google Patents

前列腺素d2受体拮抗剂的磷酸二氢盐 Download PDF

Info

Publication number
CN101287714B
CN101287714B CN2006800378860A CN200680037886A CN101287714B CN 101287714 B CN101287714 B CN 101287714B CN 2006800378860 A CN2006800378860 A CN 2006800378860A CN 200680037886 A CN200680037886 A CN 200680037886A CN 101287714 B CN101287714 B CN 101287714B
Authority
CN
China
Prior art keywords
allergic
dihydrogen phosphate
column
compound
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800378860A
Other languages
English (en)
Chinese (zh)
Other versions
CN101287714A (zh
Inventor
B·朗之万
E·奥顿
D·谢勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of CN101287714A publication Critical patent/CN101287714A/zh
Application granted granted Critical
Publication of CN101287714B publication Critical patent/CN101287714B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2006800378860A 2005-10-13 2006-10-12 前列腺素d2受体拮抗剂的磷酸二氢盐 Expired - Fee Related CN101287714B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72629005P 2005-10-13 2005-10-13
US60/726,290 2005-10-13
PCT/US2006/039901 WO2007047378A2 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (2)

Publication Number Publication Date
CN101287714A CN101287714A (zh) 2008-10-15
CN101287714B true CN101287714B (zh) 2011-04-06

Family

ID=37963090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800378860A Expired - Fee Related CN101287714B (zh) 2005-10-13 2006-10-12 前列腺素d2受体拮抗剂的磷酸二氢盐

Country Status (35)

Country Link
US (1) US7642249B2 (cg-RX-API-DMAC10.html)
EP (1) EP1948620B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009511591A (cg-RX-API-DMAC10.html)
KR (1) KR101365480B1 (cg-RX-API-DMAC10.html)
CN (1) CN101287714B (cg-RX-API-DMAC10.html)
AR (1) AR058085A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006304187B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0617311A2 (cg-RX-API-DMAC10.html)
CA (1) CA2625563C (cg-RX-API-DMAC10.html)
CR (1) CR9870A (cg-RX-API-DMAC10.html)
DK (1) DK1948620T3 (cg-RX-API-DMAC10.html)
DO (2) DOP2006000220A (cg-RX-API-DMAC10.html)
EC (1) ECSP088362A (cg-RX-API-DMAC10.html)
ES (1) ES2409833T3 (cg-RX-API-DMAC10.html)
GT (1) GT200600457A (cg-RX-API-DMAC10.html)
HN (1) HN2008000603A (cg-RX-API-DMAC10.html)
HR (1) HRP20130341T1 (cg-RX-API-DMAC10.html)
IL (1) IL190673A (cg-RX-API-DMAC10.html)
MA (1) MA30005B1 (cg-RX-API-DMAC10.html)
MY (1) MY145648A (cg-RX-API-DMAC10.html)
NI (1) NI200800116A (cg-RX-API-DMAC10.html)
NO (1) NO20082072L (cg-RX-API-DMAC10.html)
NZ (1) NZ567433A (cg-RX-API-DMAC10.html)
PE (1) PE20070791A1 (cg-RX-API-DMAC10.html)
PL (1) PL1948620T3 (cg-RX-API-DMAC10.html)
PT (1) PT1948620E (cg-RX-API-DMAC10.html)
RS (1) RS52799B (cg-RX-API-DMAC10.html)
RU (1) RU2419614C2 (cg-RX-API-DMAC10.html)
SI (1) SI1948620T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN08131A1 (cg-RX-API-DMAC10.html)
TW (1) TW200728288A (cg-RX-API-DMAC10.html)
UA (1) UA93062C2 (cg-RX-API-DMAC10.html)
UY (1) UY29862A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007047378A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200802586B (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
ATE531699T1 (de) * 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US20100112606A1 (en) * 2008-10-17 2010-05-06 Michael Armstrong Measurement and analysis of leukotrienes
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2011014587A2 (en) 2009-07-31 2011-02-03 Amira Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
EP2590640A1 (en) 2010-07-08 2013-05-15 Ramot at Tel-Aviv University Ltd Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP6770522B2 (ja) 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
DK3302448T3 (da) 2015-06-04 2024-02-05 Aurigene Oncology Ltd Erstattede heterocyclylafledninger som cdk-inhibitore
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
KR100768609B1 (ko) * 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
HRP20130341T1 (en) 2013-05-31
EP1948620A2 (en) 2008-07-30
HK1125133A1 (en) 2009-07-31
IL190673A (en) 2011-12-29
CA2625563C (en) 2011-04-19
DK1948620T3 (da) 2013-06-24
EP1948620B1 (en) 2013-03-20
PL1948620T3 (pl) 2013-08-30
SI1948620T1 (sl) 2013-05-31
CR9870A (es) 2008-06-18
DOP2006000223A (es) 2007-05-15
WO2007047378A2 (en) 2007-04-26
IL190673A0 (en) 2008-11-03
CA2625563A1 (en) 2007-04-26
RU2419614C2 (ru) 2011-05-27
MA30005B1 (fr) 2008-12-01
MY145648A (en) 2012-03-15
RS52799B (sr) 2013-10-31
NZ567433A (en) 2010-06-25
ECSP088362A (es) 2008-05-30
KR20080057275A (ko) 2008-06-24
UA93062C2 (ru) 2011-01-10
PT1948620E (pt) 2013-05-06
UY29862A1 (es) 2007-05-31
BRPI0617311A2 (pt) 2011-07-19
KR101365480B1 (ko) 2014-02-21
ZA200802586B (en) 2009-09-30
ES2409833T8 (es) 2013-09-26
NI200800116A (es) 2011-12-15
JP2009511591A (ja) 2009-03-19
WO2007047378A3 (en) 2007-08-02
AU2006304187A1 (en) 2007-04-26
AU2006304187B2 (en) 2011-04-28
US7642249B2 (en) 2010-01-05
RU2008118491A (ru) 2009-11-20
US20080194600A1 (en) 2008-08-14
PE20070791A1 (es) 2007-08-16
TW200728288A (en) 2007-08-01
AR058085A1 (es) 2008-01-23
NO20082072L (no) 2008-05-02
HN2008000603A (es) 2010-11-03
DOP2006000220A (es) 2007-05-15
CN101287714A (zh) 2008-10-15
ES2409833T3 (es) 2013-06-28
TNSN08131A1 (en) 2009-07-14
GT200600457A (es) 2007-04-27

Similar Documents

Publication Publication Date Title
US7642249B2 (en) Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist
EP2066628B1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CA2893510C (en) Compounds and their methods of use
KR20210098960A (ko) Helios의 소분자 분해제 및 사용 방법
JP2009533473A (ja) プロスタグランジンｄ２受容体アンタゴニストとしての２，６−置換−４−モノ置換アミノ−ピリミジン
JP2015091881A (ja) ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
TW201200133A (en) Substituted pyrimidines as prostaglandin D2 receptor antagonists
WO2012159557A1 (zh) 取代的三嗪苯脲衍生物及其抗肿瘤应用
JP2008528606A (ja) プロスタグランジンｄ２受容体アンタゴニストとしての２−フェニル−インドール類
JP2019142893A (ja) ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法
JP6591529B2 (ja) 置換二環式ジヒドロピリミジノンおよび好中球エラスターゼ活性の阻害薬としてのそれらの使用
SK283833B6 (sk) Deriváty benzoxadiazolu, benzotiadiazolu, benzotriazolu a chinoxalínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
JP2021519316A (ja) Ｔｌｒ２シグナル伝達の調節剤としての化合物
CN107849045B (zh) 嘌呤基-n-羟基嘧啶甲酰胺衍生物及其制备方法和用途
CN114149424A (zh) 用于治疗疾病的杂环化合物
CN115803321B (zh) 用于治疗疼痛的作为hmrgx1受体的增强剂的4-(2,6-二氟苯氧基)-6-(三氟甲基)嘧啶-2-胺衍生物
CN106231900A (zh) 化合物及其使用方法
CN116655497A (zh) 脒类衍生化合物及其制备方法和用途
MX2012010038A (es) Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
HK1125133B (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
CN120152958A (zh) 化合物及其在治疗神经变性病症和癌症中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125133

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1125133

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110406

Termination date: 20141012

EXPY Termination of patent right or utility model